DOI QR코드

DOI QR Code

Contralateral Breast Cancer: a Clinico-pathological Study of Second Primaries in Opposite Breasts after Treatment of Breast Malignancy

  • Shankar, Abhishek (Department of Radiation Oncology, IRCH, All India Institute of Medical Sciences) ;
  • Roy, Shubham (Department of Pediatrics, VMMC & Safdarjung Hospital) ;
  • Malik, Abhidha (Department of Radiation Oncology, IRCH, All India Institute of Medical Sciences) ;
  • Kamal, Vineet Kumar (Department of Bio-Statistics, All India Institute of Medical Sciences) ;
  • Bhandari, Ruchir (Department of Radiation Oncology, IRCH, All India Institute of Medical Sciences) ;
  • Kishor, Kunal (Department of Radiation Oncology, IRCH, All India Institute of Medical Sciences) ;
  • Mahajan, M.K. (Department of Bio-Statistics, All India Institute of Medical Sciences) ;
  • Sachdev, Jaineet (Department of Bio-Statistics, All India Institute of Medical Sciences) ;
  • Jeyaraj, Pamela (Department of Bio-Statistics, All India Institute of Medical Sciences) ;
  • Rath, G.K. (Department of Radiation Oncology, IRCH, All India Institute of Medical Sciences)
  • Published : 2015.03.04

Abstract

Background: Breast cancer is by far the most frequent cancer of women (23 % of all cancers), ranking second overall when both sexes are considered together. Contralateral breast cancer (CBC) is becoming an important public health issue because of the increased incidence of primary breast cancer and improved survival. The present communication concerns a study to evaluate the role of various clinico-pathological factors on the occurrence of contralateral breast cancer. Materials and Methods: A detailed analysis was carried out with respect to age, menopausal status, family history, disease stage, surgery performed, histopathology, hormone receptor status, and use of chemotherapy or hormonal therapy. The diagnosis of CBC was confirmed on histopathology report. Relative risk with 95%CI was calculated for different risk factors of contralateral breast cancer development. Results: CBC was found in 24 (4.5%) out of 532 patients. Mean age of presentation was 43.2 years. Family history of breast cancer was found in 37.5% of the patients. There was statistically significant higher rate (83.3%) of CBC in patients in age group of 20-40 years with RR=11.3 (95% CI: 1.4, 89.4, p=0.006) seen in 20-30 years and RR=10.8 (95% CI:1.5-79.6, p=0.002) in 30-40 years as compared to older age of 60-70 years. Risk of development was higher in premenopausal women (RR=8.6, 95% CI: 3.5-21.3, $p{\leq}0.001$). Women with family history of breast cancer had highest rate (20.9%) of CBC (RR=5.4, 95% CI: 2.5-11.6, $p{\leq}0.001$). Use of hormonal therapy in hormone receptor positive patients was protective factor in occurrence of CBC but not significant (RR=0.7, 95% CI: 0.3-1.5, p=0.333). Conclusions: Younger age, premenopausal status, and presence of family history were found to be significant risk factors for the development of CBC. Use of hormonal therapy in hormone receptor positive patients might be protective against occurrence of CBC but did not reach significance.

Keywords

Contralateral breast cancer;second primary;opposite breast;risk factors

References

  1. Krishnappa R, Chikaraddi SB, Deshmane V (2015). Primary synchronous bilateral breast cancer. Indian J Cancer, 51, 256-8.
  2. Lizarraga IM, Sugg SL, Weigel RJ, Scott-Conner CE (2013). Review of risk factors for the development of contralateral breast cancer. Am J Surg, 206, 704-8. https://doi.org/10.1016/j.amjsurg.2013.08.002
  3. Loi S, Haibe-Kains B, Desmedt C, et al (2007). Definition of clinically distinct molecular subtypes in estrogen receptorpositive breast carcinomas through genomic grade. J Clin Oncol, 25, 1239-46. https://doi.org/10.1200/JCO.2006.07.1522
  4. Mariana L, Coradina D, Biganzoli E, et al (1997). Prognostic factors for metachronous contralateral breast cancer: a comparison of linear Cox regression model and its artificial neural network extension. Breast Cancer Res Treat, 44, 167-71. https://doi.org/10.1023/A:1005765403093
  5. Mellemkjaer L, Steding-Jessen M, Frederiksen K, et al (2014, In press). Risk of contralateral breast cancer after tamoxifen use among Danish women. Ann epemiol, 24, 843-8
  6. Nichols HB, Berrington de Gonzalez A, et al (2011). Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol, 29, 1564-9. https://doi.org/10.1200/JCO.2010.32.7395
  7. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  8. Phillips KA, Milne RL, Rookus MA, et al (2013). Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol, 31, 3091-9. https://doi.org/10.1200/JCO.2012.47.8313
  9. Rebegea L, Firescu D, Anghel R, Dumitru M (2013). Clinical and therapeutical aspects of contralateral breast cancer after treatment of breast neoplasm. J Radiotherapy Med Oncol, 19, 45-8.
  10. Reiner AS, John EM, Brooks JD, et al (2013). Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the women's environmental cancer and radiation epidemiology study. J Clin Oncol, 31, 433-9. https://doi.org/10.1200/JCO.2012.43.2013
  11. Rusner C, Wolf K, Bandemer-Greulich U, et al (2014). Risk of contralateral second primary breast cancer according to hormone receptor status in Germany. Breast Cancer Res, 16, 4.
  12. Shim HJ, Kim SH, Kang BJ, et al (2014). Breast cancer recurrence according to molecular subtype. Asian Pac J Cancer Prev, 15, 5539-44. https://doi.org/10.7314/APJCP.2014.15.14.5539
  13. Silber JH, Rosenbaum PR, Clark AS, et al (2013). Characteristics associated with differences in survival among black and white women with breast cancer. JAMA, 310, 389-97. https://doi.org/10.1001/jama.2013.8272
  14. Stewart HJ (1992). The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. J Natl Cancer Inst Monogr, 11, 117-20.
  15. Aihara T, Tanaka S, Sagara Y, et al (2014). Incidence of contralateral breast cancer in Japanese patients with unilateral minimum-risk primary breast cancer, and the benefits of endocrine therapy and radiotherapy. Breast Cancer, 21, 284-91. https://doi.org/10.1007/s12282-012-0396-4
  16. Allred DC, Anderson SJ, Paik S, et al (2012). Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol, 30, 1268-73. https://doi.org/10.1200/JCO.2010.34.0141
  17. Arriagada R, Rutqvist LE (1991). Adjuvant chemotherapy in early breast cancer and incidence of new primary malignancies. Lancet, 338, 535-8. https://doi.org/10.1016/0140-6736(91)91100-9
  18. Bessonova L, Taylor TH, Mehta RS, et al (2011). Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer. Cancer Epidemiol Biomarkers Prev, 20, 389-96. https://doi.org/10.1158/1055-9965.EPI-10-1016
  19. Cancer Research Campaign Breast Cancer Trials Group (1992). The effect of adjuvant tamoxifen: the latest results from the cancer research campaign adjuvant breast trial. Eur J Cancer, 28, 904-7. https://doi.org/10.1016/0959-8049(92)90147-T
  20. Chen Y, Thompson W, Semenciw R, et al (1999). Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev, 8, 855-61.
  21. Early Breast Cancer Trialists' Collaborative Group (1992). Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet, 339, 1-15-7185.
  22. Early Breast Cancer Trialists Collaborative Group (1998). Tamoxifen for early breast cancer: an overview of randomized trials. Lancet, 351, 1451-67. https://doi.org/10.1016/S0140-6736(97)11423-4
  23. Gao X, Fisher SG, Emami B (2003). Risk of second primary cancer in the contralateral breast in women treated for earlystage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys, 56, 1038-45. https://doi.org/10.1016/S0360-3016(03)00203-7
  24. Hankey BF, Curtis RE, Naughton MD, et al (1983). A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the effects of radiation therapy. J Natl Cancer Ins, 70, 797-804.
  25. Heron DE, Komarnicky LT, Hyslop T, et al (2000). Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer, 88, 2739-50. https://doi.org/10.1002/1097-0142(20000615)88:12<2739::AID-CNCR12>3.0.CO;2-J
  26. Horn-Ross PL (1993). Multiple primary cancers involving the breast. Epidemiol Rev, 15, 169-76.
  27. Howlader N, Noone AM, Krapcho M, et al (????). SEER Cancer statistics review, 1975-2009 (vintage 2009 populations), National Cancer Institute, USA.
  28. Kilgore AR (1921). The incidence of cancer in the second breast. J Am Med Assoc, 77, 454-7. https://doi.org/10.1001/jama.1921.02630320038011
  29. Storm HH, Andersson M, Boice JD, et al (1992). Adjuvant radiotherapy and risk of contralateral breast cancer. J Natl Cancer Inst, 84, 1245-50. https://doi.org/10.1093/jnci/84.16.1245
  30. Storm HH, Andersson M, Boice JD, et al (1992). Adjuvant radiotherapy and risk of contralateral breast cancer. J Natl Cancer Inst, 84, 1245-50. https://doi.org/10.1093/jnci/84.16.1245
  31. Yadav BS, Sharma SC, Patel FD, et al (2008). Second primary in the contralateral breast after treatment of breast cancer. Radiotherapy Oncol, 86, 171-6. https://doi.org/10.1016/j.radonc.2007.10.002
  32. Zeichner SB, Ruiz AL , Markward NJ, Rodriguez E (2014). Improved long-term survival with contralateral prophylactic mastectomy among young women. Asian Pac J Cancer Prev, 15, 1155-62. https://doi.org/10.7314/APJCP.2014.15.3.1155
  33. Abbott A, Rueth N, Pappas-Varco S, et al (2011). Perceptions of contralateral breast cancer: an overestimation of risk. Ann Surg Oncol, 18, 3129-36. https://doi.org/10.1245/s10434-011-1914-x

Cited by

  1. Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033) vol.18, pp.1, 2016, https://doi.org/10.1186/s13058-016-0752-y